Elderly patients with community-acquired pneumonia: optimal treatment strategies (Q37896600)

25 August 2017

1 reference

title

Elderly patients with community-acquired pneumonia: optimal treatment strategies (English)

1 reference

25 August 2017

0 references

Ulrich Thiem

1

1 reference

25 August 2017

Hans-Jürgen Heppner

series ordinal

2

1 reference

25 August 2017

Ludger Pientka

series ordinal

3

1 reference

25 August 2017

publication date

1 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

28

1 reference

25 August 2017

issue

7

1 reference

25 August 2017

page(s)

519-537

1 reference

Prospective study of the aetiology and outcome of pneumonia in the community

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Age still matters: Prognosticating short- and long-term mortality for critically ill patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

How important is age in defining the prognosis of patients with community-acquired pneumonia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Influence of age on symptoms at presentation in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

21 January 2018

Pneumonia in the elderly

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Healthcare-associated pneumonia: the state of evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Why mortality is increased in health-care-associated pneumonia: lessons from pneumococcal bacteremic pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Nursing home-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Prospective study of community-acquired pneumonia of bacterial etiology in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Bacteraemic pneumococcal pneumonia: a continuously evolving disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Predicting antimicrobial resistance in invasive pneumococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Pneumonia in the elderly: a review of the epidemiology, pathogenesis, microbiology, and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Rapid universal identification of bacterial pathogens from clinical cultures by using a novel sloppy molecular beacon melting temperature signature technique

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Current applications and future trends of molecular diagnostics in clinical bacteriology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Bacterial species identification from MALDI-TOF mass spectra through data analysis and machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of clinically relevant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Infection by drug-resistant Streptococcus pneumoniae is not linked to increased mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Serotype distribution and antimicrobial resistance of adult Streptococcus pneumoniae clinical isolates over the period 2001-2008 in Crete, Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Two novel assays for the detection of haemin-binding properties of antimalarials evaluated with compounds isolated from medicinal plants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Macrolide resistance in bacteremic pneumococcal disease: implications for patient management.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Respiratory infections due to drug-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

CRB-65 predicts death from community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Validation of predictive rules and indices of severity for community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Severe community-acquired pneumonia. Assessment of severity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Imaging of pneumonia: trends and algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Diagnostic value of chest radiographs in bedridden patients suspected of having pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Chronic kidney disease in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Drug dosing in the elderly patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Safety considerations of fluoroquinolones in the elderly: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Antibacterial agents in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Principles of antimicrobial use in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Unique aspects of antimicrobial use in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Drug interactions during therapy with three major groups of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Maintaining fluoroquinolone class efficacy: review of influencing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Community-acquired pneumonia: impact of immune status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for o

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Immunomodulatory activities of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Azithromycin and lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Induction of beta-lactamase and methicillin resistance in unusual strains of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Using assessing care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Implementing a hospital guideline on pneumonia: a semi-quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Community-acquired pneumonia: process of care studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Guidelines and critical pathways for severe hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Nursing home-acquired pneumonia: update on treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Current and Potential Usefulness of Pneumococcal Urinary Antigen Detection in Hospitalized Patients With Community-Acquired Pneumonia to Guide Antimicrobial Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591980-000000000-00000

Etiology of severe pneumonia in the very elderly

21 January 2018

1 reference

12 December 2020

Prognosis of patients hospitalized with community-acquired pneumonia

1 reference

12 December 2020

Comparison of the sensitivity of the Legionella urinary antigen EIA kits from Binax and Biotest with urine from patients with infections caused by less common serogroups and subgroups of Legionella

1 reference

12 December 2020

Appropriately assessing renal function for drug dosing

1 reference

12 December 2020

Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae--United States, 2006-2007.

1 reference

12 December 2020

A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit

1 reference

12 December 2020

Ten-year surveillance of invasive Streptococcus pneumoniae isolates in central Turkey prior to the introduction of a conjugate vaccine

1 reference

12 December 2020

Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia.

1 reference

12 December 2020

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis

1 reference

12 December 2020

Modifiable Risk Factors for Nursing Home-Acquired Pneumonia

1 reference

12 December 2020

Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004)

1 reference

12 December 2020

Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975.

1 reference

12 December 2020

Time to first antibiotic dose measurement in community-acquired pneumonia: time for a change

1 reference

12 December 2020

Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial

1 reference

12 December 2020

Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study

1 reference

12 December 2020

Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects

1 reference

12 December 2020

Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin

1 reference

12 December 2020

The pharmacokinetics of azithromycin in human serum and tissues

1 reference

12 December 2020

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

1 reference

12 December 2020

Antibiotics for community acquired pneumonia in adult outpatients

1 reference

12 December 2020

Clinical implications of the immunomodulatory effects of macrolides

1 reference

12 December 2020

Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group

1 reference

12 December 2020

Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes

1 reference

12 December 2020

Rapid diagnostic testing for community-acquired pneumonia: can innovative technology for clinical microbiology be exploited?

1 reference

12 December 2020

Community-acquired pneumonia in elderly patients

1 reference

12 December 2020

Cefepime: a review of its use in the management of hospitalized patients with pneumonia

1 reference

12 December 2020

Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia

1 reference

12 December 2020

[Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)]

1 reference

12 December 2020

Community-acquired pneumonia

1 reference

12 December 2020

Management of community-acquired pneumonia in adults

1 reference

12 December 2020

Pneumonia in the elderly

1 reference

12 December 2020

Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin

1 reference

12 December 2020

Clostridium difficile infection

1 reference

12 December 2020

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Molecular virology in the clinical laboratory.

1 reference

12 December 2020

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

12 December 2020

Radiology of pneumonia

1 reference

12 December 2020

Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia

1 reference

12 December 2020

10.2165/11591980-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1032617975

0 references

1 reference